Leila Cysique Foinlan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Leila Cysique Foinlan has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Ahmadreza Arbab
Universite Paris-Saclay, Gustave Roussy, Departement de biologie et pathologie medicales, INSERM U1363 Biotherapies Innovantes, F-94805, Villejuif, France
1 shared publication - Aline Renneville
INSERM U1287, Gustave Roussy, Université Paris-Saclay, Villejuif, France
1 shared publication Annabelle Stoclin
Gustave Roussy
1 shared publicationCaroline Pradon
Gustave Roussy
1 shared publicationChristophe Marzac
Gustave Roussy
1 shared publicationChristophe Willekens
INSERM U1287, Gustave Roussy, Paris-Saclay University, Villejuif, France
1 shared publication
Latest Publications
- Top Cited PapersOpen Access
- 24 April 2024
- Published by Springer Nature in Blood Cancer Journal
- Vol. 14 (1) , 1-12
RAS mutations in myeloid malignancies: revisiting old questions with novel insights and therapeutic perspectives
NRAS and KRAS activating point mutations are present in 10–30% of myeloid malignancies and are often associated with a proliferative phenotype. RAS mutations harbor allele-specific structural and biochemical properties depending on the hotspot mutation, contributing to variable biological consequences. Given their subclonal nature in most myeloid malignancies, their clonal architecture, and patterns of cooperativity with other driver genetic alterations may potentially have a direct, causal influence on the prognosis and treatment of myeloid malignancies. RAS mutations overall tend to be associated with poor clinical outcome in both chronic and acute myeloid malignancies. Several recent prognostic scoring systems have incorporated RAS mutational status. While RAS mutations do not always act as independent prognostic factors, they significantly influence disease progression and survival. However, their clinical significance depends on the type of mutation, disease context, and treatment administered. Recent evidence also indicates that RAS mutations drive resistance to targeted therapies, particularly FLT3, IDH1/2, or JAK2 inhibitors, as well as the venetoclax-azacitidine combination. The investigation of novel therapeutic strategies and combinations that target multiple axes within the RAS pathway, encompassing both upstream and downstream components, is an active field of research. The success of direct RAS inhibitors in patients with solid tumors has brought renewed optimism that this progress will be translated to patients with hematologic malignancies. In this review, we highlight key insights on RAS mutations across myeloid malignancies from the past decade, including their prevalence and distribution, cooperative genetic events, clonal architecture and dynamics, prognostic implications, and therapeutic targeting.
- 24 April 2024
- Published by Springer Nature in Blood Cancer Journal
- Vol. 14 (1) , 1-12
Top Cited PapersOpen AccessRAS mutations in myeloid malignancies: revisiting old questions with novel insights and therapeutic perspectives
NRAS and KRAS activating point mutations are present in 10–30% of myeloid malignancies and are often associated with a proliferative phenotype. RAS mutations harbor allele-specific structural and biochemical properties depending on the hotspot mutation, contributing to variable biological consequences. Given their subclonal nature in most myeloid malignancies, their clonal architecture, and patterns of cooperativity with other driver genetic alterations may potentially have a direct, causal influence on the prognosis and treatment of myeloid malignancies. RAS mutations overall tend to be associated with poor clinical outcome in both chronic and acute myeloid malignancies. Several recent prognostic scoring systems have incorporated RAS mutational status. While RAS mutations do not always act as independent prognostic factors, they significantly influence disease progression and survival. However, their clinical significance depends on the type of mutation, disease context, and treatment administered. Recent evidence also indicates that RAS mutations drive resistance to targeted therapies, particularly FLT3, IDH1/2, or JAK2 inhibitors, as well as the venetoclax-azacitidine combination. The investigation of novel therapeutic strategies and combinations that target multiple axes within the RAS pathway, encompassing both upstream and downstream components, is an active field of research. The success of direct RAS inhibitors in patients with solid tumors has brought renewed optimism that this progress will be translated to patients with hematologic malignancies. In this review, we highlight key insights on RAS mutations across myeloid malignancies from the past decade, including their prevalence and distribution, cooperative genetic events, clonal architecture and dynamics, prognostic implications, and therapeutic targeting.
- Open Access
- 23 April 2023
- Published by Wiley
An atypical promyelocytic sarcoma in a pleural effusion: efficacy of ATRA/ATO treatment
Myeloid sarcoma is a rare extramedullary tumoral infiltration of immature myeloid cells and can occur in different sites of the body, without leukemic infiltration A 38-year-old woman patient presented at emergency with a pleural effusion and bicytopenias. In the following days, she worsened with a chylothorax and pancytopenias. Pleural puncture cytologically
- 23 April 2023
- Published by Wiley
Open AccessAn atypical promyelocytic sarcoma in a pleural effusion: efficacy of ATRA/ATO treatment
Myeloid sarcoma is a rare extramedullary tumoral infiltration of immature myeloid cells and can occur in different sites of the body, without leukemic infiltration A 38-year-old woman patient presented at emergency with a pleural effusion and bicytopenias. In the following days, she worsened with a chylothorax and pancytopenias. Pleural puncture cytologically